奥尔波特综合征：事实与观点。
Alport syndrome: facts and opinions.
作者信息
Kashtan Clifford
机构信息
Department of Pediatrics, Division of Pediatric Nephrology, University of Minnesota Medical School, Minneapolis, MN, USA.
出版信息
F1000Res. 2017 Jan 17;6:50. doi: 10.12688/f1000research.9636.1. eCollection 2017.
Abstract
In this commentary, I review recent advances in Alport syndrome genetics, diagnostics, and therapeutics. I also offer some opinions regarding strategies to optimize the early identification of affected individuals to promote early therapeutic intervention.
摘要
在这篇评论中，我回顾了奥尔波特综合征在遗传学、诊断和治疗方面的最新进展。我还就优化受影响个体的早期识别策略以促进早期治疗干预提出了一些看法。
相似文献
1
Alport syndrome: facts and opinions.
F1000Res. 2017 Jan 17;6:50. doi: 10.12688/f1000research.9636.1. eCollection 2017.
2
X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype Correlations.
PLoS One. 2016 Sep 14;11(9):e0161802. doi: 10.1371/journal.pone.0161802. eCollection 2016.
3
Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene.
Kidney Int. 2004 May;65(5):1598-603. doi: 10.1111/j.1523-1755.2004.00560.x.
4
Alport syndrome and thin basement membrane nephropathy.
Nephron Clin Pract. 2007;106(2):c82-8. doi: 10.1159/000101802. Epub 2007 Jun 6.
5
COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome.
Kidney Int. 2001 Aug;60(2):480-3. doi: 10.1046/j.1523-1755.2001.060002480.x.
6
Clinical and molecular diagnosis of Alport syndrome.
Proc Assoc Am Physicians. 1995 Oct;107(3):306-13.
7
Collagen type IV nephropathy: genetic heterogeneity examinations in affected Hungarian families.
Mol Cell Probes. 2011 Feb;25(1):28-34. doi: 10.1016/j.mcp.2010.10.001. Epub 2010 Oct 14.
8
Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome.
Hum Mutat. 2005 Jul;26(1):60. doi: 10.1002/humu.9349.
9
COL4A4-related nephropathy caused by a novel mutation in a large consanguineous Saudi family.
Int J Pediatr Otorhinolaryngol. 2014 Mar;78(3):427-32. doi: 10.1016/j.ijporl.2013.12.008. Epub 2013 Dec 18.
10
COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome.
Kidney Int. 2002 Jun;61(6):1947-56. doi: 10.1046/j.1523-1755.2002.00379.x.
引用本文的文献
1
Detection of haematuria and proteinuria reflects injury to significantly different glomerular surface areas: a quantitative hypothesis.
Clin Kidney J. 2025 Jul 31;18(8):sfaf245. doi: 10.1093/ckj/sfaf245. eCollection 2025 Aug.
2
Lithuanian Study on and Genetic Variants in Alport Syndrome: Clinical Characterization of 52 Individuals from 38 Families.
Int J Mol Sci. 2025 Aug 7;26(15):7639. doi: 10.3390/ijms26157639.
3
Collagen type IV alpha 6 promotes tumor progression and chemoresistance in ovarian cancer by activating the discoidin domain receptor 1 pathway.
Oncogenesis. 2025 Jul 2;14(1):23. doi: 10.1038/s41389-025-00565-2.
4
Carrier screening for Alport syndrome: The clinical importance of heterozygosity for pathogenic or likely pathogenetic variants.
J Genet Couns. 2025 Jun;34(3):e70045. doi: 10.1002/jgc4.70045.
5
Phenotype-genotype correlations in patients with Alport syndrome from the Polish population.
J Nephrol. 2025 Apr 16. doi: 10.1007/s40620-025-02251-3.
6
Alport Syndrome: A Comprehensive Review.
Cureus. 2023 Oct 16;15(10):e47129. doi: 10.7759/cureus.47129. eCollection 2023 Oct.
7
Ocular Manifestations and Potential Treatments of Alport Syndrome: A Systematic Review.
J Ophthalmol. 2022 Sep 8;2022:9250367. doi: 10.1155/2022/9250367. eCollection 2022.
8
Identification of a novel pathogenic gene mutation in a Chinese family with autosomal dominant Alport syndrome: A case report.
Biomed Rep. 2021 Nov;15(5):90. doi: 10.3892/br.2021.1466. Epub 2021 Aug 30.
9
Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Int J Med Sci. 2021 Apr 26;18(12):2521-2531. doi: 10.7150/ijms.59177. eCollection 2021.
10
Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.
Int J Mol Sci. 2021 May 28;22(11):5808. doi: 10.3390/ijms22115808.
本文引用的文献
1
Three-dimensional electron microscopy reveals the evolution of glomerular barrier injury.
Sci Rep. 2016 Oct 11;6:35068. doi: 10.1038/srep35068.
2
Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice.
Hear Res. 2016 Nov;341:100-108. doi: 10.1016/j.heares.2016.08.003. Epub 2016 Aug 21.
3
Alport Syndrome in Women and Girls.
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1713-1720. doi: 10.2215/CJN.00580116. Epub 2016 Jun 10.
4
A novel COL4A1 frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen.
Nephrol Dial Transplant. 2016 Nov;31(11):1908-1914. doi: 10.1093/ndt/gfw051. Epub 2016 Apr 8.
5
Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease.
Kidney Int. 2016 Aug;90(2):300-310. doi: 10.1016/j.kint.2016.02.018. Epub 2016 Apr 27.
6
Albumin contributes to kidney disease progression in Alport syndrome.
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F120-30. doi: 10.1152/ajprenal.00456.2015. Epub 2016 May 4.
7
Preclinical Alterations in the Serum of COL(IV)A3(-)/(-) Mice as Early Biomarkers of Alport Syndrome.
J Proteome Res. 2015 Dec 4;14(12):5202-14. doi: 10.1021/acs.jproteome.5b00814. Epub 2015 Nov 3.
8
Evidence of digenic inheritance in Alport syndrome.
J Med Genet. 2015 Mar;52(3):163-74. doi: 10.1136/jmedgenet-2014-102822. Epub 2015 Jan 9.
9
Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.
J Clin Invest. 2015 Jan;125(1):141-56. doi: 10.1172/JCI75852. Epub 2014 Nov 21.
10
Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis.
PLoS One. 2014 Jun 10;9(6):e99083. doi: 10.1371/journal.pone.0099083. eCollection 2014.
Zotero 插件